{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:40:34Z","timestamp":1761100834140},"reference-count":69,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1016\/j.beha.2005.07.009","type":"journal-article","created":{"date-parts":[[2006,6,15]],"date-time":"2006-06-15T13:25:13Z","timestamp":1150377913000},"page":"519-533","source":"Crossref","is-referenced-by-count":16,"title":["Hemopoietic cell transplantation as curative therapy of myelodysplastic syndromes and myeloproliferative disorders"],"prefix":"10.1016","volume":"19","author":[{"given":"Bart","family":"Scott","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Joachim","family":"Deeg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2005.07.009_bib1","series-title":"Hematology: Basic Principles and Practice","first-page":"1106","article-title":"Myelodysplastic syndrome","author":"Greenberg","year":"2000"},{"key":"10.1016\/j.beha.2005.07.009_bib2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1182\/blood.V74.1.395.395","article-title":"Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients","volume":"74","author":"Sanz","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.beha.2005.07.009_bib3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"The French-American-British (FAB) co-operative group: proposals for the classification of the myelodysplastic syndromes","volume":"51","author":"Bennett","year":"1982","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2005.07.009_bib4","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","article-title":"World health organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting\u2014Airlie House, Virginia, November 1997","volume":"17","author":"Harris","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2005.07.009_bib5","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes (erratum appears in Blood Feb 1; 91(3): 1100)","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.beha.2005.07.009_bib6","first-page":"1997","article-title":"Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia","volume":"100","author":"Sierra","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2005.07.009_bib7","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1002\/1097-0142(19910515)67:10<2658::AID-CNCR2820671042>3.0.CO;2-C","article-title":"Life expectancy of patients with chronic nonleukemic myeloproliferative disorders","volume":"67","author":"Rozman","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2005.07.009_bib8","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2141.1988.tb02507.x","article-title":"A prognostic classification of myelofibrosis with myeloid metaplasia","volume":"70","author":"Barosi","year":"1988","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2005.07.009_bib9","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","article-title":"Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system","volume":"88","author":"Dupriez","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.beha.2005.07.009_bib10","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood.V99.3.840","article-title":"Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients","volume":"99","author":"Onida","year":"2002","journal-title":"Blood"},{"issue":"supplement 7","key":"10.1016\/j.beha.2005.07.009_bib11","first-page":"95","article-title":"Bone marrow transplantation: a review","volume":"36","author":"Thomas","year":"1999","journal-title":"Semin Hematol"},{"key":"10.1016\/j.beha.2005.07.009_bib12","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2004-01-0338","article-title":"A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome","volume":"104","author":"Cutler","year":"2004","journal-title":"Blood"},{"issue":"supplement 1","key":"10.1016\/j.beha.2005.07.009_bib13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.bbmt.2004.12.067","article-title":"Hematopoietic cell transplantation (HCT)-specific-comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"11","author":"Sorror","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2005.07.009_bib14","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1182\/blood.V98.8.2326","article-title":"Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS","volume":"98","author":"de Witte","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2005.07.009_bib15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.bbmt.2004.10.001","article-title":"Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome","volume":"11","author":"Scott","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2005.07.009_bib16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2141.1990.tb02558.x","article-title":"Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG)","volume":"74","author":"de Witte","year":"1990","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2005.07.009_bib17","doi-asserted-by":"crossref","first-page":"590","DOI":"10.7326\/0003-4819-112-8-590","article-title":"Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome","volume":"112","author":"Appelbaum","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.beha.2005.07.009_bib18","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1200\/JCO.1996.14.1.220","article-title":"Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors","volume":"14","author":"Anderson","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2005.07.009_bib19","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1046\/j.1365-2141.1996.4811022.x","article-title":"Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia","volume":"93","author":"Anderson","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2005.07.009_bib20","first-page":"745","article-title":"Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors","volume":"17","author":"Demuynck","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2005.07.009_bib21","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1182\/blood.V88.1.358.358","article-title":"Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Societe Francaise de Greffe de Moelle","volume":"88","author":"Sutton","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.beha.2005.07.009_bib22","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood.V92.6.1910","article-title":"Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation","volume":"92","author":"Nevill","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.beha.2005.07.009_bib23","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/sj.bmt.1701084","article-title":"Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic leukemia working party of the european group for blood and marrow transplantation","volume":"21","author":"Runde","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2005.07.009_bib24","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/sj.bmt.1701269","article-title":"Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey, european blood and marrow transplantation group","volume":"21","author":"Arnold","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2005.07.009_bib25","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1182\/blood.V95.4.1188.004k38_1188_1194","article-title":"Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55\u201366 years of age","volume":"95","author":"Deeg","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.beha.2005.07.009_bib26","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1046\/j.1365-2141.2000.02200.x","article-title":"Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the chronic Leukaemia working party of the european group for blood and marrow transplantation (EBMT)","volume":"110","author":"de Witte","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2005.07.009_bib27","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/sj.leu.2402296","article-title":"Genotypically nonidentical related donors for transplantation of patients with myelodysplastic syndromes: comparison with unrelated donor transplantation and autologous stem cell transplantation","volume":"15","author":"de Witte","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2005.07.009_bib28","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1182\/blood.V99.6.1943","article-title":"Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the national marrow donor program","volume":"99","author":"Castro-Malaspina","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2005.07.009_bib29","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood-2002-02-0527","article-title":"Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome","volume":"100","author":"Deeg","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2005.07.009_bib30","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1053\/bbmt.2002.v8.pm11939606","article-title":"Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality","volume":"8","author":"Jurado","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2005.07.009_bib31","first-page":"445","article-title":"Treatment of myelodysplastic syndrome with busulfan-cyclophosphamide conditioning followed by allogeneic BMT","volume":"10","author":"Nevill","year":"1992","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2005.07.009_bib32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood.V87.1.51.51","article-title":"Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors","volume":"87","author":"Anderson","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.beha.2005.07.009_bib33","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/sj.bmt.1702432","article-title":"Analysis of prognostic factors for allogeneic marrow transplantation following busulfan and cyclophosphamide in myelodysplastic syndrome and after leukemic transformation","volume":"25","author":"Copelan","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2005.07.009_bib34","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1182\/blood.V99.12.4370","article-title":"Subcommittee for Myelodysplastic syndromes of the chronic Leukaemia working group of the european blood and marrow transplantation group: retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes","volume":"99","author":"Guardiola","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2005.07.009_bib35","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1200\/JCO.1990.8.10.1707","article-title":"Bone marrow transplantation for myelodysplasia and secondary acute nonlymphoblastic leukemia","volume":"8","author":"Longmore","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2005.07.009_bib36","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1182\/blood.V81.8.2194.2194","article-title":"Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes","volume":"81","author":"Ratanatharathorn","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.beha.2005.07.009_bib37","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1200\/JCO.1995.13.12.2973","article-title":"Busulfan\/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia","volume":"13","author":"O'Donnell","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2005.07.009_bib38","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/sj.bmt.1700739","article-title":"Outcome of allogeneic bone marrow transplantation with lymphocyte-depleted marrow grafts in adult patients with myelodysplastic syndromes","volume":"19","author":"Mattijssen","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2005.07.009_bib39","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1046\/j.1365-2141.1999.01205.x","article-title":"Treatment of advanced myelodysplastic syndrome with a regimen including recombinant human granulocyte colony-stimulating factor preceding allogeneic bone marrow transplantation","volume":"104","author":"Okamoto","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2005.07.009_bib40","first-page":"157","article-title":"Allogeneic stem cell transplantation for patients with high-risk myelodysplastic syndrome","volume":"98","author":"Hsu","year":"1999","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.beha.2005.07.009_bib41","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1053\/bbmt.2001.v7.pm11302550","article-title":"Relapse after allogeneic bone marrow transplantation for refractory anemia is increased by shielding lungs and liver during total body irradiation","volume":"7","author":"Anderson","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2005.07.009_bib42","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ajh.1121","article-title":"Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia","volume":"67","author":"Bibawi","year":"2001","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2005.07.009_bib43","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1182\/blood-2002-11-3567","article-title":"Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells","volume":"102","author":"Bornh\u00e4user","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2005.07.009_bib44","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1182\/blood-2004-02-0414","article-title":"Once-daily intravenous buslfan and fludarabine: clinical and pharmacokinetic results of a myeloabltive, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS","volume":"104","author":"de Lima","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2005.07.009_bib45","first-page":"743","article-title":"Allogeneic bone marrow transplantation for primary myelofibrosis","volume":"16","author":"Singhal","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2005.07.009_bib46","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1046\/j.1365-2141.1997.3073124.x","article-title":"French society of BMT: allogeneic bone marrow transplantation for agnogenic myeloid metaplasia","volume":"98","author":"Guardiola","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2005.07.009_bib47","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1046\/j.1365-2141.1997.3083125.x","article-title":"Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis","volume":"98","author":"Anderson","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2005.07.009_bib48","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/(SICI)1096-8652(199801)57:1<24::AID-AJH4>3.0.CO;2-3","article-title":"Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases (Review)","volume":"57","author":"Przepiorka","year":"1998","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2005.07.009_bib49","unstructured":"van Besien K, Deeg HJ. Hemopoietic stem cell transplantation for myelofibrosis (Review). Semin Oncol; in press."},{"key":"10.1016\/j.beha.2005.07.009_bib50","first-page":"2831","article-title":"Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle, Gruppo Italiano per il Trapianto del midollo osseo, and Fred Hutchinson cancer research center collaborative study","volume":"93","author":"Guardiola","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.beha.2005.07.009_bib51","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1182\/blood-2003-06-1856","article-title":"Allogeneic hematopoietic stem cell transplantation for myelofibrosis","volume":"102","author":"Deeg","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2005.07.009_bib52","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1080\/1042819022386626","article-title":"Curative therapy of advanced essential thrombocythemia or polycythemia vera by hemopoietic stem cell transplantation","volume":"43","author":"Platzbecker","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2005.07.009_bib53","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1046\/j.1365-2141.2000.02133.x","article-title":"Treatment of chronic myelomonocytic leukaemia by allogeneic marrow transplantation","volume":"110","author":"Zang","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2005.07.009_bib54","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2141.2002.03552.x","article-title":"Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the chronic Leukaemia working party of the European group for blood and marrow transplantation (EBMT)","volume":"118","author":"Kroger","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2005.07.009_bib55","first-page":"3853","article-title":"Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS","volume":"90","author":"de Witte","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.beha.2005.07.009_bib56","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/sj.leu.2401387","article-title":"A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes","volume":"13","author":"Wattel","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2005.07.009_bib57","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1182\/blood.V98.3.586","article-title":"Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis","volume":"98","author":"Anderson","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2005.07.009_bib58","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/sj.bmt.1702204","article-title":"Mini-allografts: ongoing trials in humans (Editorial)","volume":"25","author":"Carella","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2005.07.009_bib59","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/sj.bmt.1703215","article-title":"A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome","volume":"28","author":"Kroger","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2005.07.009_bib60","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2002-02-0400","article-title":"AML and alloPBSCT subcommittees of the Spanish group for hematopoietic transplantation: evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes","volume":"100","author":"Martino","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2005.07.009_bib61","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1182\/blood-2003-12-4207","article-title":"Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan and alemtuzumab (FBC) conditioning","volume":"104","author":"Ho","year":"2004","journal-title":"Blood"},{"issue":"Part 1","key":"10.1016\/j.beha.2005.07.009_bib62","first-page":"185a","article-title":"Efficacy of non-myeloablative allogeneic transplant for patients with myelodysplastic syndrome (MDS) and myeloproliferative disorders (MPD) (except chronic myelogenous leukemia)","volume":"102","author":"Stuart","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2005.07.009_bib63","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1182\/blood.V99.6.2255","article-title":"Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia","volume":"99","author":"Devine","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2005.07.009_bib64","first-page":"199a","article-title":"Non-myeloablative allogeneic HSCT in high risk patients with myelofibrosis","volume":"102","author":"Rondelli","year":"2003","journal-title":"Blood"},{"issue":"Part 1","key":"10.1016\/j.beha.2005.07.009_bib65","first-page":"89a","article-title":"Similar outcome of non-myeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients greater than fifty years of age","volume":"104","author":"Alyea","year":"2004","journal-title":"Blood"},{"issue":"Part 1","key":"10.1016\/j.beha.2005.07.009_bib66","first-page":"638a","article-title":"Myeloablative versus nonmyeloablative hemopoietic cell transplantation (HCT) for patients with myelodysplasia (MDS) or AML with multinlineage dysplasia following MDS (tAML)","volume":"104","author":"Scott","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2005.07.009_bib67","first-page":"209","article-title":"Hemopoietic cell transplantation for myelodysplastic syndromes","volume":"2","author":"Benesch","year":"2003","journal-title":"Curr Hematol Rep"},{"key":"10.1016\/j.beha.2005.07.009_bib68","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1182\/blood-2002-09-2768","article-title":"Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hemopoietic stem cell transplantation","volume":"102","author":"Wells","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2005.07.009_bib69","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1182\/blood-2003-02-0482","article-title":"HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies","volume":"102","author":"Maris","year":"2003","journal-title":"Blood"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692605000964?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692605000964?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T14:08:31Z","timestamp":1586959711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692605000964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["S1521692605000964"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2005.07.009","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}